Pulmatrix (PULM) Other Accumulated Expenses (2014 - 2026)
Pulmatrix (PULM) posted Other Accumulated Expenses of $10000.0 for Q1 2026, down 28.57% sequentially from $14000.0 in Q4 2025, and down 91.07% YoY from $112000.0 in Q1 2025.
Pulmatrix (PULM) Other Accumulated Expenses (2014 - 2026) Analysis & Trends
Pulmatrix has reported Other Accumulated Expenses for 13 years, with the latest figure at $10000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 91.07% year-over-year to $10000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10000.0 (down 91.07% YoY) and the FY2025 annual result came in at $14000.0, down 80.28% from the prior year.
- Other Accumulated Expenses fell to $10000.0 in Q1 2026 per PULM's latest filing, from $14000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $222000.0 in Q1 2023 and troughed at $10000.0 in Q1 2026.
- A 5-year average of $92823.5 and a median of $80000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses soared 280.49% in 2022, then plunged 91.07% in 2026.
- Over 5 years, Other Accumulated Expenses stood at $33000.0 in 2022, then surged by 200.0% to $99000.0 in 2023, then retreated by 28.28% to $71000.0 in 2024, then tumbled by 80.28% to $14000.0 in 2025, then retreated by 28.57% to $10000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $10000.0, $14000.0, and $76000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 112,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 99,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 94,000.00 |
| Mar 31, 2023 | 222,000.00 |
| Dec 31, 2022 | 33,000.00 |
| Sep 30, 2022 | 156,000.00 |
| Jun 30, 2022 | 131,000.00 |
| Mar 31, 2022 | 80,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 41,000.00 |